Lead optimization through VLAK protocol: New annelated pyrrolo-pyrimidine derivatives as antitumor agents
Authors:
- Antonino LauriaALAntonino Lauria
- Chiara PatellaCPChiara Patella
- Ilenia AbbateIAIlenia Abbate
- Annamaria MartoranaAMAnnamaria Martorana
- Anna Maria AlmericoAAAnna Maria Almerico
- 1 September 2012
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 55, 375-383
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Virtual lock-and-key approach: The in silico revival of Fischer model by means of molecular descriptorsEuropean Journal of Medicinal Chemistry, 2011
- Principal component analysis on molecular descriptors as an alternative point of view in the search of new Hsp90 inhibitorsComputational Biology and Chemistry, 2009
- Combined Use of PCA and QSAR/QSPR to Predict the Drugs Mechanism of Action. An Application to the NCI ACAM DatabaseQSAR & Combinatorial Science, 2009
- Design and Synthesis of 4-Substituted Indolo[3,2-e][1,2,3]triazolo[1,5-a]pyrimidine Derivatives with Antitumor ActivityJournal of Medicinal Chemistry, 2008
- Annelated pyrrolo-pyrimidines from amino-cyanopyrroles and BMMAs as leads for new DNA-interactive ring systemsBioorganic & Medicinal Chemistry, 2005
- Use of the Kohonen Self-organizing Map to Study the Mechanisms of Action of Chemotherapeutic AgentsJNCI: Journal of the National Cancer Institute, 1994
- Neural Computing in Cancer Drug Development: Predicting Mechanism of ActionScience, 1992
- Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell LinesJNCI: Journal of the National Cancer Institute, 1991
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI: Journal of the National Cancer Institute, 1990
- Faraday lecture. Synthetical chemistry in its relation to biologyJournal of the Chemical Society, Transactions, 1907